{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:44Z","timestamp":1785132104125,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a chronic inflammatory disease with substantial pruritic burden. Abrocitinib, an oral selective Janus kinase 1 (JAK1) inhibitor, targets cytokine pathways central to AD pathophysiology. This systematic review and meta-analysis evaluated its efficacy and safety in moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance, PubMed, Embase, Web of Science, and the Cochrane Library were searched to 21 August 2025 for randomized controlled trials (RCTs) comparing abrocitinib with placebo. Two reviewers independently screened studies, extracted data, and assessed risk of bias (Cochrane RoB 2.0). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated; model choice was based on heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five double-blind placebo-controlled RCTs involving 1,927 patients were included. Abrocitinib significantly improved Investigator\u2019s Global Assessment response (RR = 2.97, 95% CI: 2.45\u20133.60), Eczema Area and Severity Index-75 response (RR = 2.56, 95% CI: 2.25\u20132.92), and \u22654-point Peak Pruritus Numerical Rating Scale improvement (RR = 2.64, 95% CI: 2.29\u20133.06), with greater efficacy observed for 200\u00a0mg than 100\u00a0mg. Treatment-emergent adverse events were increased (RR = 1.18, 95% CI: 1.10\u20131.27), mainly nausea (RR = 5.53, 95% CI: 3.41\u20139.34). Headache was also increased overall (RR = 1.64, 95% CI: 1.16\u20132.47), whereas skin allergy was reduced (RR = 0.58, 95% CI: 0.44\u20130.82).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Abrocitinib provides clinically meaningful short-term improvements in disease severity and pruritus in moderate-to-severe AD. The 200\u00a0mg dose offers greater efficacy but requires careful monitoring for tolerability, particularly nausea and headache.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1735556","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:35Z","timestamp":1785130835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the JAK1 inhibitor abrocitinib for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Bobiao","family":"Ning","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Myopia Prevention and Control Center, Eye Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Guangzhou Dermatology Hospital","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiyuan Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.18176\/jiaci.0906","article-title":"Updated review on treatment of atopic dermatitis","volume":"33","author":"Armario-Hita","year":"2023","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/imt-2021-0224","article-title":"Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary","volume":"14","author":"Bieber","year":"2022","journal-title":"Immunotherapy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic Versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.4103\/idoj.idoj_449_24","article-title":"Abrocitinib: a comprehensive review of its efficacy and safety in dermatology","volume":"15","author":"Dogra","year":"2024","journal-title":"Indian Dermatol Online J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/lexb9006","article-title":"Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis","volume":"28","author":"Edwards","year":"2024","journal-title":"Health Technol. Assess."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","article-title":"Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib","volume":"21","author":"Ferreira","year":"2020","journal-title":"Am. J. Clin. Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/pharmaceutics15020385","article-title":"Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis","volume":"15","author":"Iznardo","year":"2023","journal-title":"Pharmaceutics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"adv19454","DOI":"10.2340\/actadv.v104.19454","article-title":"Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay registry","volume":"104","author":"Kamphuis","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40257-023-00837-w","article-title":"Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors","volume":"25","author":"Kim","year":"2024","journal-title":"Am. J. Clin. Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cea.70125","article-title":"Real-world effectiveness and safety of JAK inhibitors in atopic dermatitis: a systematic review and meta-analysis","volume":"55","author":"Kim","year":"2025","journal-title":"Clin. Exp. Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1154949","DOI":"10.3389\/fphar.2023.1154949","article-title":"Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/all.16495","article-title":"Real-world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: a single-center prospective study","volume":"80","author":"Li","year":"2025","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: emerging topical and oral janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1358\/dot.2022.58.8.3408817","article-title":"Abrocitinib in atopic dermatitis: review of the current literature and clinical trials","volume":"58","author":"Napolitano","year":"2022","journal-title":"Drugs Today (Barc)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2020-8\u20135","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"key":"B21","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/cells13050425","article-title":"Unraveling atopic dermatitis: insights into pathophysiology, therapeutic advances, and future perspectives","volume":"13","author":"Pareek","year":"2024","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","article-title":"Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","article-title":"Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther. (Heidelb)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am. J. Clin. Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1735556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:40:35Z","timestamp":1785130835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1735556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":28,"alternative-id":["10.3389\/fphar.2026.1735556"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1735556","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1735556"}}